Yes, testosterone can still be prescribed through telehealth as of this writing, with more conditions than most online prescriptions. Under the DEA telemedicine rule, testosterone gets extra scrutiny because it is a Schedule III controlled substance. Temporary federal flexibilities currently allow telemedicine prescribing without a prior in-person visit. A permanent framework that would cover testosterone has not been finalized, and what comes next may depend on whether your prescriber has seen you in person.
Key takeaways
- Testosterone is a Schedule III controlled substance, so federal rules on remote prescribing apply to it in ways they don't apply to most medications prescribed online (DailyMed label).
- Temporary federal flexibilities currently allow controlled substances, including testosterone, to be prescribed by telemedicine without a prior in-person visit, under conditions.
- DEA has proposed a permanent framework for telemedicine prescribing, and as of this writing, DEA has not published a final version of the broad framework that would cover testosterone.
- Your situation once the temporary flexibilities end may depend on what DEA publishes and on whether your prescriber has ever evaluated you in person.
- Whatever the rules turn out to be, guideline-based diagnosis depends on confirmed lab results, which makes a live clinician visit plus lab work the sound standard for testosterone.
Can testosterone be prescribed through telehealth in 2026?
Yes, with conditions. Temporary federal flexibilities, which began during the COVID-19 public health emergency, let a DEA-registered practitioner prescribe controlled substances, including testosterone, by telemedicine without first seeing the patient in person.
In general terms, any controlled-substance prescription must meet a few baseline conditions:
- The prescription is for a legitimate medical purpose, written in the usual course of professional practice.
- The prescriber holds a DEA registration.
- The prescriber follows the law of the state where you are located.
The temporary flexibilities also set conditions on how the telemedicine encounter itself takes place. The exact requirements are in the official federal text, and a legitimate provider should be able to explain how it meets them.
There is also a clinical floor that sits underneath any legal minimum. Diagnosing low testosterone depends on confirmed lab results and an evaluation of symptoms, as covered later in this article. A questionnaire-only or chat-only route to testosterone skips that, and that is a process problem worth noticing.
DEA telemedicine rule, testosterone and Schedule III
Testosterone gets extra rules because it is a controlled substance. FDA-approved testosterone cypionate labels state that the product contains testosterone, a Schedule III controlled substance under the Controlled Substances Act (DailyMed label). Another label notes that testosterone is controlled under the Anabolic Steroid Control Act and lists it as DEA Schedule CIII (DailyMed label).
Schedule III is a federal category for drugs with accepted medical uses and some potential for abuse or dependence. Placement there means stricter rules on how the drug is prescribed, dispensed and tracked.
The labels' drug abuse sections give useful context. Testosterone has been abused, typically at doses higher than those recommended and often alongside other anabolic androgenic steroids. That kind of abuse can lead to serious cardiovascular and psychiatric adverse reactions, and it has been seen in adult men, adult women and adolescents (DailyMed label). A current label also describes dependence behaviors linked to continued abuse, such as taking more than prescribed (DailyMed, 2025).
Most medications people get through telehealth are not controlled substances, so this federal layer doesn't touch them. Scheduling is not a judgment about men on prescribed therapy. It sets the level of oversight around the drug.
The Ryan Haight Act in plain English
The Ryan Haight Online Pharmacy Consumer Protection Act is the federal law behind the in-person requirement. In general, it requires at least one in-person medical evaluation before a practitioner prescribes controlled substances remotely, with limited exceptions.
Three points patients often miss:
- A live video visit is not an in-person medical evaluation under this law. The two are legally different, however thorough the video visit is.
- The relationship that matters is between you and the practitioner who prescribes. An in-person visit with someone else doesn't automatically carry over to a different prescriber. Ask how this applies to you.
- Before the pandemic, the usual order was an in-person evaluation first, with telehealth follow-ups after that.
Once a prescriber has done that in-person evaluation, the Act's in-person requirement has generally been met for that relationship. State rules and other federal requirements still apply.
The temporary flexibilities are a pause on the in-person requirement. They don't repeal it. That is why their end matters.
What happens when the temporary flexibilities end?
No one knows yet. The flexibilities have been carried forward by temporary extensions, DEA has proposed a permanent framework, and as of this writing, DEA has not published a final version of that framework.
The proposed framework is often described as a special registration for telemedicine. In broad terms, it would create a separate DEA registration for clinicians who prescribe controlled substances by telemedicine without an in-person evaluation. Proposals can change substantially before a final rule, so treat any detailed description of the proposal as provisional.
| Question | Status as of this writing |
|---|---|
| Is telehealth prescribing of testosterone allowed now? | Yes, under temporary federal flexibilities with conditions |
| Is a permanent framework planned? | DEA has proposed one; not yet finalized |
| What a final rule requires, and when it takes effect | Unknown |
When the current flexibilities end, there are broadly three possibilities. A final rule could be in effect, the temporary flexibilities could be extended again, or they could lapse without a replacement. None of these is certain.
Two habits help here. First, check the date on anything you read about DEA telemedicine policy, because older articles often describe plans that are no longer current. Second, treat confident predictions about the final rule as guesses until DEA publishes official text in the Federal Register. Regulatory status can change after this article is published.
Already on testosterone? Where you might stand later
It depends on two things: which rules are in force when the temporary flexibilities end, and whether your prescriber has ever seen you in person.
| Your situation | How the in-person rule applies | What to watch |
|---|---|---|
| Your prescriber has evaluated you in person at least once | The in-person evaluation requirement has generally been met for that relationship | State rules and your provider's own policies |
| You have only ever been seen by telehealth | Your path depends on what DEA publishes | Whether your prescriber registers under a final rule, or whether an in-person evaluation is needed |
| You are new to testosterone therapy and have not been seen in person | Same as the row above | Same as the row above |
State law can add requirements on top of federal rules, and those differ from state to state. Your provider should be able to explain how your state's rules apply.
Questions worth asking your current provider now, before any deadline arrives:
- Is my prescriber registered with DEA?
- Has my prescriber, specifically, ever evaluated me in person?
- How will you follow whatever rule is in force when the temporary flexibilities end?
- When are my next labs due?
Don't change or stop your medication on your own because of a headline. Talk with your clinician before making any change to your therapy. This section is general information, not legal advice.
Why a live visit and lab work are the right standard either way
A live visit and labs matter because diagnosing low testosterone and monitoring therapy both depend on them. That would be true even if the DEA rule disappeared tomorrow.
The Endocrine Society's clinical practice guideline recommends diagnosing hypogonadism only in men who have symptoms and signs consistent with testosterone deficiency and unequivocally, consistently low testosterone (Endocrine Society, JCEM 2018). Hypogonadism means the body isn't producing enough testosterone. The guideline recommends:
- a fasting morning total testosterone test with an accurate, reliable assay, confirmed by a repeat fasting morning test
- a free testosterone measurement when total testosterone is near the lower limit of normal or when sex hormone-binding globulin (SHBG), a protein that carries testosterone in the blood, may be altered
- further evaluation to find the cause of the deficiency
- a discussion of benefits, risks and monitoring before therapy, with the patient involved in decisions
During treatment, the guideline suggests aiming for testosterone in the mid-normal range, weighing patient preference, how the medication behaves in the body, adverse effects, treatment burden and cost (Endocrine Society, JCEM 2018). That target can only be checked with follow-up labs.
FDA labels add to the case for oversight. A current FDA-approved testosterone cypionate label warns about venous thromboembolism (blood clots in the veins) and blood pressure increases, and FDA’s 2025 class-wide update removed an earlier cardiovascular risk warning (DailyMed, 2025). Labels also tell clinicians to check serum testosterone if abuse is suspected, to confirm levels are within the therapeutic range (DailyMed label).
For the specific tests, see our guide to TRT blood work before and during therapy. For the cardiovascular data, see what the TRAVERSE trial showed about TRT and heart risk. For symptoms and the basics of testing, see low testosterone symptoms and testing.
The red flags are about process. Be wary of testosterone offered after a form alone, without lab work, or without a live clinician. A service that skips these steps is cutting corners on the clinical standard, whatever the regulatory picture. Our guide on how to spot a legitimate telehealth provider covers more of these signals.
How access works through New Blue
New Blue is a technology and administrative services platform. Medical services are provided by independent licensed clinicians; medications are dispensed only if prescribed.
Every testosterone pathway, including the injectable testosterone protocol, is synchronous. That means a live clinician visit plus lab work, not an asynchronous form.
- Complete an intake.
- Have a live visit with an independent licensed clinician and complete lab work.
- The clinician decides whether therapy is appropriate based on your intake, visit and labs.
- If prescribed, a licensed partner pharmacy ships the medication directly to you.
Not everyone qualifies. Eligibility depends on your intake and clinical review, and that's how it should work. How care is delivered after the temporary flexibilities end will follow the federal and state rules in force at that time.
Availability varies by state; check state availability. Adults 21 and older only. Not for emergencies. New Blue is LegitScript certified. Consultation timing varies by clinician availability. If treatment isn't appropriate, refunds follow our refund policy. For current pricing and details, see the injectable testosterone protocol page.
Frequently Asked Questions
Is testosterone a controlled substance?
Yes. FDA-approved testosterone labels state that testosterone is a Schedule III controlled substance under the Controlled Substances Act. Labels also note that testosterone has been abused, typically at higher-than-recommended doses, and that this kind of abuse can cause serious cardiovascular and psychiatric harm.
Does the DEA rule apply to testosterone cream or oral testosterone too?
Generally, yes. FDA labels describe testosterone itself as the Schedule III substance, so controlled-substance rules attach to the ingredient rather than to one format. Ask your prescriber how the rules apply to the specific product you use.
Does a video visit count as an in-person evaluation?
No. Under the Ryan Haight Act, a live video visit is not an in-person medical evaluation. The current temporary flexibilities allow telemedicine prescribing without a prior in-person visit, but they don't turn a video visit into an in-person evaluation.
Has DEA finalized a permanent telemedicine framework?
As of this writing, DEA has not published a final version of the broad telemedicine framework that would cover testosterone. DEA has proposed a permanent framework for clinicians who prescribe controlled substances by telemedicine, but proposals can change before they are finalized. Official text appears in the Federal Register.
Will telehealth testosterone therapy end when the temporary rules expire?
Nobody knows yet. When the current flexibilities end, a final rule could be in effect, the flexibilities could be extended again, or they could lapse without a replacement. Patients whose prescriber has evaluated them in person may be affected differently from patients seen only by telehealth.
Can I get testosterone online without a live visit?
Responsible telehealth testosterone care includes a live visit with a clinician and lab work. Guideline-based diagnosis depends on confirmed morning testosterone tests and a clinical evaluation, which a form alone cannot provide. A form-only offer for testosterone is a red flag.
Sources
- Testosterone cypionate injection, solution: label. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6909596e-4bf7-4e11-8029-b89740a30aec
- Testosterone cypionate injection, USP: label. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a34023dc-fc54-4f66-bab0-9596502c23a3
- AZMIRO (testosterone cypionate) injection: label. DailyMed, U.S. National Library of Medicine, 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235b5625-570d-3fba-e063-6394a90aa2d1
- Bhasin et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology and Metabolism, 2018. https://pubmed.ncbi.nlm.nih.gov/29562364/
Medical disclaimer: This article is educational and is not medical or legal advice. Treatment decisions are made by a licensed clinician based on your individual history, evaluation and lab work. New Blue Health is a technology and administrative services platform, not a medical provider.
Related treatment guide
Related reading
Content review & editorial standards
This page is educational content from the New Blue Health Editorial Team. It is checked under the New Blue Health Content Review Policy and Editorial Policy and should not replace individualized medical advice from a licensed clinician. For how we evaluate evidence, see Evidence Methodology and Clinical Sources & References.